Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

BOPA/ISOPP 2019 View overview page

1:48
Pharmacy perspective: pembrolizumab monotherapy 6 weekly dosing
Rob Duncombe • 10 Oct 2019
4:47
Embracing the challenges of aseptic compounding services
Tim Root • 10 Oct 2019
0:59
Audit of rapid infusion of biosimilar rituximab
Calum Polwart • 10 Oct 2019
4:52
Cancer Associated Thrombosis (CAT): risk factors and improving awareness
Simon Noble • 10 Oct 2019
1:03
Global oncology pharmacy collaboration: ISOPP and BOPA
Rob Duncombe • 10 Oct 2019
3:49
Cyto-SAT: self-assessment tool for the safe handling of cytotoxic medicines
Sandrine von Grünigen • 10 Oct 2019
3:25
Oncology pharmacy in Japan
Shinya Suzuki • 10 Oct 2019
4:06
Cancer treatment: major milestones & what’s next in the 2020s
John Wagstaff • 10 Oct 2019
2:19
Can spinners improve understanding of adverse events in patients with cancer?
Lisa Holle • 10 Oct 2019
3:43
Pediatric medication dose banding: the Canadian experience
Mary Gunther • 10 Oct 2019
1:48
Educating and encouraging the public to question non-evidence based medicine
Michael Marshall • 10 Oct 2019
1:39
Pharmacist and nurse-led melanoma immunotherapy clinic
Dharmisha Chauhan • 10 Oct 2019
2:19
Benefits of ISOPP: one Italian pharmacist’s experience
Felice Musicco • 10 Oct 2019
4:48
Minimizing the risk of steroid-induced hyperglycemia in NSCLC patients receiving immunotherapy
Islam Elkonaissi • 10 Oct 2019
2:29
Dose banding in oncology
Calum Polwart • 10 Oct 2019
5:04
Medicinal cannabis in cancer patients – is there a benefit?
Carlo DeAngelis • 10 Oct 2019
The content of VJOncology is intended for healthcare professionals